Charles River Laboratories Intl. Inc vs Global X Autonomous & Electric Vehicles — how do they compare? Charles River Laboratories Intl. Inc trades at $231 (market cap $11.14B), while Global X Autonomous & Electric Vehicles trades at $36.09. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Global X Autonomous & Electric Vehicles nearer its low. Which is the better fit depends on your goals.
| CRL | DRIV | |
|---|---|---|
Market Cap | $11.14B | — |
Sector | Health | Sector/Thematic |
52-Week High | $233.60 | $42.53 |
52-Week Low | $145.57 | $23.67 |
Enterprise Value | $14.00B | — |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
DRIV trades at $35.37, down 3.2% on the day amid a bearish technical signal. The stock faces selling pressure with moving averages indicating a downtrend, though oversold RSI levels suggest potential near-term support. Recent news highlights strong global EV sales growth and China's aggressive expansion, providing a favorable industry backdrop for this electric vehicle-focused ETF.
The outlook remains cautious due to technical weakness, though industry momentum from rising EV adoption offers long-term growth potential. Key risks include regulatory uncertainty around Chinese vehicles and potential tariff impacts. Investors should monitor technical levels for stabilization signs amid volatile market conditions.
Trailing returns across standard periods
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.
Read more on DRIV →